Advertisement

Mold Infections After Hematopoietic Stem Cell Transplantation

  • Kieren A. Marr
Chapter

Abstract

Fungi, especially those caused by yeasts and molds, have been a major concern in transplantation for many years. Shortly after successful strategies were adopted to prevent candidiasis, infections caused by molds emerged as the prominent problem. Epidemiology and outcomes studies performed in the 1990s demonstrated that mold infections, especially invasive pulmonary aspergillosis, had become a leading cause of infection during both the early pre-engraftment and late post-allogeneic transplant time periods, with high rates of death. Today, both the epidemiology and outcomes of mold infections have changed, in large part associated with earlier diagnosis and increased use of azole-based therapies. This chapter will review historical changes, update diagnostics and therapies, and discuss emerging issues that are likely to warrant more attention in the future.

Keywords

Aspergillosis Mold infections Stem cell transplantation 

References

  1. 1.
    Short DP, O’Donnell K, Thrane U, Nielsen KF, Zhang N, Juba JH, et al. Phylogenetic relationships among members of the Fusarium solani species complex in human infections and the descriptions of F. keratoplasticum sp. nov. and F. petroliphilum stat. nov. Fungal Genet Biol. 2013;53:59–70.PubMedCrossRefGoogle Scholar
  2. 2.
    O’Donnell K, Sutton DA, Fothergill A, McCarthy D, Rinaldi MG, Brandt ME, et al. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol. 2008;46(8):2477–90.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell. 2006;5(10):1705–12.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell. 2005;4(3):625–32.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Balajee SA, Baddley JW, Peterson SW, Nickle D, Varga J, Boey A, et al. Aspergillus alabamensis, a new clinically relevant species in the section Terrei. Eukaryot Cell. 2009;8(5):713–22.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother. 2011;55(10):4802–9.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Varga J, Houbraken J, Van Der Lee HA, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell. 2008;7(4):630–8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Bizet J, Cooper CJ, Zuckerman MJ, Torabi A, Mendoza-Ladd A. A bleeding colonic ulcer from invasive Aspergillus infection in an immunocompromised patient: a case report. J Med Case Reports. 2014;8:407.CrossRefGoogle Scholar
  9. 9.
    Gupta V, Rajagopalan N, Patil M, Shivaprasad C. Aspergillus and mucormycosis presenting with normal chest X-ray in an immunocompromised host. BMJ Case Rep. 2014;2014.Google Scholar
  10. 10.
    Lunde LE, Chuang C, Linden MA, Williams SA, Sachs Z, Cayci Z, et al. Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction. Am J Hematol. 2013;88(4):329–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Chasan R, Patel G, Malone A, Finn M, Huprikar S. Primary hepatic aspergillosis following induction chemotherapy for acute leukemia. Transpl Infect Dis. 2013;15(5):E201–5.PubMedGoogle Scholar
  12. 12.
    Winkler S, Susani S, Willinger B, Apsner R, Rosenkranz AR, Potzi R, et al. Gastric mucormycosis due to Rhizopus oryzae in a renal transplant recipient. J Clin Microbiol. 1996;34(10):2585–7.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Stewart JI, D’Alonzo GE, Ciccolella DE, Patel NB, Durra H, Clauss HE. Reverse halo sign on chest imaging in a renal transplant recipient. Transpl Infect Dis. 2014;16(1):115–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Agarwal R, Aggarwal AN, Gupta D. Another cause of reverse halo sign: Wegener’s granulomatosis. Br J Radiol. 2007;80(958):849–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhan X, Zhang L, Wang Z, Jin M, Liu M, Tong Z. Reversed halo sign: presents in different pulmonary diseases. PLoS One. 2015;10(6), e0128153.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011;52(9):1144–55.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Jung J, Kim MY, Lee HJ, Park YS, Lee SO, Choi SH, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect. 2015;21(7):684 e11–8.Google Scholar
  18. 18.
    Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175(6):1459–66.PubMedCrossRefGoogle Scholar
  19. 19.
    Wingard JR, Beals SU, Santos GW, Merz WG, Saral R. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant. 1987;2(2):175–81.PubMedGoogle Scholar
  20. 20.
    Domenech C, Leick-Courtois C, Bienvenu AL, Pracros JP, Picot S, Bleyzac N, et al. Improvement in the outcome of invasive aspergillosis in a pediatric hematology department: a 10-year review. J Pediatr Hematol Oncol. 2015;37(7):560–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50(12):1559–67.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Parody R, Martino R, Sanchez F, Subira M, Hidalgo A, Sierra J. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol. 2009;84(9):571–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Cordonnier C, Ribaud P, Herbrecht R, Milpied N, Valteau-Couanet D, Morgan C, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis. 2006;42(7):955–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–66.PubMedCrossRefGoogle Scholar
  26. 26.
    Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.PubMedCrossRefGoogle Scholar
  27. 27.
    Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis. 2003;16(6):607–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989–2006. Clin Infect Dis. 2006;43(12):1580–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21(1):157–97.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol. 2000;111(1):272–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54 Suppl 1:S16–22.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Riches ML, Trifilio S, Chen M, Ahn KW, Langston A, Lazarus HM, et al. Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. Bone Marrow Transplant. 2015;51:277–82.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Panackal AA, Li H, Kontoyiannis DP, Mori M, Perego CA, Boeckh M, et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis. 2010;50(12):1588–97.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367(23):2214–25.PubMedCrossRefGoogle Scholar
  37. 37.
    Park SY, Lim C, Lee SO, Choi SH, Kim YS, Woo JH, et al. Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value. J Infect. 2011;63(6):447–56.PubMedCrossRefGoogle Scholar
  38. 38.
    Warrilow AG, Parker JE, Price CL, Nes WD, Kelly SL, Kelly DE. In vitro biochemical study of CYP51-mediated azole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2015;59:7771–8.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009;9(12):789–95.PubMedCrossRefGoogle Scholar
  40. 40.
    Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(4):647–55.PubMedCrossRefGoogle Scholar
  41. 41.
    Reichenberger F, Habicht J, Matt P, Frei R, Soler M, Bolliger CT, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant. 1999;24(11):1195–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4(6):349–57.PubMedCrossRefGoogle Scholar
  43. 43.
    Miceli MH, Maertens J. Role of non-culture-based tests, with an emphasis on galactomannan testing for the diagnosis of invasive aspergillosis. Semin Respir Crit Care Med. 2015;36(5):650–61.PubMedCrossRefGoogle Scholar
  44. 44.
    Hsu LY, Ding Y, Phua J, Koh LP, Chan DS, Khoo KL, et al. Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients. BMC Infect Dis. 2010;10:44.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Heng SC, Morrissey O, Chen SC, Thursky K, Manser RL, Nation RL, et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol. 2015;41(1):124–34.PubMedCrossRefGoogle Scholar
  46. 46.
    Tortorano AM, Esposto MC, Prigitano A, Grancini A, Ossi C, Cavanna C, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol. 2012;50(3):1051–3.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Vergidis P, Walker RC, Kaul DR, Kauffman CA, Freifeld AG, Slagle DC, et al. False-positive Aspergillus galactomannan assay in solid organ transplant recipients with histoplasmosis. Transpl Infect Dis. 2012;14(2):213–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Nucci M, Carlesse F, Cappellano P, Varon AG, Seber A, Garnica M, et al. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS One. 2014;9(1), e87784.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, et al. Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother. 2012;67(7):1746–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Kimura S, Akahoshi Y, Nakano H, Harada N, Kameda K, Ugai T, et al. False-positive Aspergillus galactomannan and its kinetics in allogeneic hematopoietic stem cell transplantation. J Infect. 2015;70(5):520–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Sulahian A, Porcher R, Bergeron A, Touratier S, Raffoux E, Menotti J, et al. Use and limits of (1-3)-beta-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol. 2014;52(7):2328–33.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Hoenigl M, Prattes J, Spiess B, Wagner J, Prueller F, Raggam RB, et al. Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2014;52(6):2039–45.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Paholcsek M, Fidler G, Konya J, Rejto L, Mehes G, Bukta E, et al. Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia. BMC Infect Dis. 2015;15:251.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Sun W, Wang K, Gao W, Su X, Qian Q, Lu X, et al. Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate metaanalysis and systematic review. PLoS One. 2011;6(12), e28467.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(2):89–96.PubMedCrossRefGoogle Scholar
  56. 56.
    Held J, Schmidt T, Thornton CR, Kotter E, Bertz H. Comparison of a novel Aspergillus lateral-flow device and the Platelia(R) galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection. 2013;41(6):1163–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Johnson GL, Sarker SJ, Nannini F, Ferrini A, Taylor E, Lass-Florl C, et al. Aspergillus-specific lateral-flow device and real-time PCR testing of bronchoalveolar lavage fluid: a combination biomarker approach for clinical diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2015;53(7):2103–8.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Dufresne SF, Datta K, Li X, Dadachova E, Staab JF, Patterson TF, et al. Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis. PLoS One. 2012;7(8), e42736.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Koo S, Thomas HR, Daniels SD, Lynch RC, Fortier SM, Shea MM, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis. 2014;59(12):1733–40.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Maschmeyer G, Neuburger S, Fritz L, Bohme A, Penack O, Schwerdtfeger R, et al. A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol. 2009;20(9):1560–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Cruciani M, Mengoli C, Loeffler J, Donnelly P, Barnes R, Jones BL, et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev. 2015;10, CD009551.Google Scholar
  62. 62.
    Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13(6):519–28.PubMedCrossRefGoogle Scholar
  63. 63.
    Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.PubMedCrossRefGoogle Scholar
  64. 64.
    Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–27.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–33.PubMedCrossRefGoogle Scholar
  67. 67.
    Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705–13.PubMedCrossRefGoogle Scholar
  68. 68.
    Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103(4):1557–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.PubMedCrossRefGoogle Scholar
  70. 70.
    Maron GM, Hayden RT, Rodriguez A, Rubnitz JE, Flynn PM, Shenep JL, et al. Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections. Pediatr Infect Dis J. 2013;32(12):e451–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Torres A, Serrano J, Rojas R, Martin V, Martin C, Tabares S, et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol. 2010;84(3):271–3.PubMedCrossRefGoogle Scholar
  72. 72.
    Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010;45(4):662–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Roman E, Osunkwo I, Militano O, Cooney E, van de Ven C, Cairo MS. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer. 2008;50(2):325–30.PubMedCrossRefGoogle Scholar
  74. 74.
    Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol. 2006;17(8):1306–12.PubMedCrossRefGoogle Scholar
  75. 75.
    Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 1999;23(2):163–8.PubMedCrossRefGoogle Scholar
  76. 76.
    van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–16.PubMedCrossRefGoogle Scholar
  77. 77.
    Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood. 1999;93(11):3654–61.PubMedGoogle Scholar
  78. 78.
    Morello E, Pagani L, Coser P, Cavattoni I, Cortelazzo S, Casini M, et al. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study. Bone Marrow Transplant. 2011;46(1):132–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Liu F, Wu T, Wang JB, Cao XY, Yin YM, Zhao YL, et al. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2013;15(3):243–50.PubMedCrossRefGoogle Scholar
  80. 80.
    Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006;108(9):2928–36.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Liu M, Li Y, Zhao X, Zhang Y, Zhai B, Zhang Q, et al. Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients. Int J Clin Exp Med. 2015;8(7):11794–802.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Cordonnier C, Rovira M, Maertens J, Cornely OA, Ljungman P, Einsele H, et al. Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. Haematologica. 2011;96(2):e9–10; author reply e1.Google Scholar
  83. 83.
    Vehreschild JJ, Sieniawski M, Reuter S, Arenz D, Reichert D, Maertens J, et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents. 2009;34(5):446–50.PubMedCrossRefGoogle Scholar
  84. 84.
    Liu Q, Lin R, Sun J, Xiao Y, Nie D, Zhang Y, et al. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis. Biol Blood Marrow Transplant. 2014;20(8):1198–203.PubMedCrossRefGoogle Scholar
  85. 85.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.PubMedCrossRefGoogle Scholar
  86. 86.
    Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61:558–65.CrossRefGoogle Scholar
  87. 87.
    Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. 2010;45(7):1227–33.PubMedCrossRefGoogle Scholar
  88. 88.
    Tragiannidis A, Groll AH. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. Clin Microbiol Infect. 2009;15 Suppl 5:82–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S, Lortholary O, et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med. 2015;36(5):692–705.PubMedCrossRefGoogle Scholar
  90. 90.
    Nucci F, Nouer SA, Capone D, Anaissie E, Nucci M. Fusariosis. Semin Respir Crit Care Med. 2015;36(5):706–14.PubMedCrossRefGoogle Scholar
  91. 91.
    Tortorano AM, Richardson M, Roilides E, van Diepeningen A, Caira M, Munoz P, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20 Suppl 3:27–46.PubMedCrossRefGoogle Scholar
  92. 92.
    Blyth CC, Gilroy NM, Guy SD, Chambers ST, Cheong EY, Gottlieb T, et al. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12b):1333–49.PubMedCrossRefGoogle Scholar
  93. 93.
    Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.PubMedCrossRefGoogle Scholar
  94. 94.
    Wiederhold NP, Patterson TF. Emergence of azole resistance in Aspergillus. Semin Respir Crit Care Med. 2015;36(5):673–80.PubMedCrossRefGoogle Scholar
  95. 95.
    Price TH. The RING study: a randomized controlled trial of GCSF-stimulated granulocytes in granulocytopenic patients. In: 56th American Society for Hematology Annual Meeting and Exposition; 2014 December 6–9; San Francisco, CA.Google Scholar
  96. 96.
    Raad II, Chaftari AM, Al Shuaibi MM, Jiang Y, Shomali W, Cortes JE, et al. Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications. Ann Oncol. 2013;24(7):1873–9.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Kadri SS, Remy KE, Strich JR, Gea-Banacloche J, Leitman SF. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion. 2015;55(9):2076–85.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Jolink H, Hagedoorn RS, Lagendijk EL, Drijfhout JW, van Dissel JT, Falkenburg JH, et al. Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis. Haematologica. 2014;99(7):1255–63.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Stuehler C, Khanna N, Bozza S, Zelante T, Moretti S, Kruhm M, et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood. 2011;117(22):5881–91.PubMedCrossRefGoogle Scholar
  100. 100.
    Stuehler C, Nowakowska J, Bernardini C, Topp MS, Battegay M, Passweg J, et al. Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J Infect Dis. 2015;211(8):1251–61.PubMedCrossRefGoogle Scholar
  101. 101.
    Bedke T, Iannitti RG, De Luca A, Giovannini G, Fallarino F, Berges C, et al. Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice. Immunol Cell Biol. 2014;92(8):659–70.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370(5):421–32.PubMedCrossRefGoogle Scholar
  103. 103.
    Grube M, Loeffler J, Mezger M, Kruger B, Echtenacher B, Hoffmann P, et al. TLR5 stop codon polymorphism is associated with invasive aspergillosis after allogeneic stem cell transplantation. Med Mycol. 2013;51(8):818–25.PubMedCrossRefGoogle Scholar
  104. 104.
    Cunha C, Aversa F, Romani L, Carvalho A. Human genetic susceptibility to invasive aspergillosis. PLoS Pathog. 2013;9(8), e1003434.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Chai LY, de Boer MG, van der Velden WJ, Plantinga TS, van Spriel AB, Jacobs C, et al. The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis. 2011;203(5):736–43.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Cunha C, Di Ianni M, Bozza S, Giovannini G, Zagarella S, Zelante T, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood. 2010;116(24):5394–402.PubMedCrossRefGoogle Scholar
  107. 107.
    Levitz SM, Shoham S, Cleary JD. Toll-like receptor 4 polymorphisms and aspergillosis. N Engl J Med. 2009;360(6):634. author reply 5–6.PubMedCrossRefGoogle Scholar
  108. 108.
    Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359(17):1766–77.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  1. 1.Department of MedicineJohns Hopkins HospitalBaltimoreUSA

Personalised recommendations